TMC Venture Fund
VC Fund
Houston, United States
TMC Venture Fund is a VC fund in Houston focused on Health Care and Medical Device. TMC Venture Fund invests in entrepreneurs who are shaping the future of health care.TMC Venture Fund's mission is to serve the world's health, education, and research needs.TMCVF is the venture capital arm of Texas Medical Center Corporation.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries TMC Venture Fund invests in
Stages TMC Venture Fund invests in
Countries TMC Venture Fund invests in
Investment Focus
Industry
- Health Care 12 (71%)
- Medical Device 6 (35%)
- Medical 4 (24%)
- Software 2 (12%)
- Life Science 2 (12%)
Stage
- Series A 6 (35%)
- Seed 5 (29%)
- Venture - Series Unknown 3 (18%)
- Series B 1 (6%)
Country
- United States 13 (76%)
- Ireland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Surf Therapeutics
|
Surf Therapeutics is a clinical-stage firm leading the development of non-invasive ultrasound neuromodulation technology to modify immune-related pathways. | $6M / Seed / Mar 17, 2026 | |
PATH EX
|
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EXis taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths. | $5M / Venture - Series Unknown / May 08, 2025 | |
Clarium
|
Clarium is transforming healthcare by empowering providers with an AI-powered platform with intelligent workflow automation and actionable insights. | $27M / Series A / May 08, 2025 | |
Lena Health
|
Text-based Health Assistant for patients. With Lena, clinics can offer callers the option to skip the long call queues and schedule their appointment via SMS-text live chat. Value-based care organizations and payers can offer members a text-based assistant that can take care of health tasks such as scheduling appointments and coordinating theircare. | $2M / Seed / Apr 22, 2025 | |
Alleviant Medical
|
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americanscurrently suffering from this disease. | $90M / Venture - Series Unknown / Jan 14, 2025 | |
NUA Surgical
|
NUA Surgical is an award-winning start-up based at the National University of Ireland it develops a specialized surgical retractor to make C-Sections a safer and superior surgery.SteriCISION will improve the ergonomics of the surgery, reduce the resources required and reduce the risk of surgical site infection. | $6.9M / Series A / Dec 06, 2024 | |
CrossBridge Bio
|
CrossBridge Bio operates as a biotechnology company, innovates ADC therapeutics through stable dual linker payload technology. | $10M / Seed / Nov 04, 2024 | |
March Biosciences
|
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | |
|
Clarium
|
Clarium is transforming healthcare by empowering providers with an AI-powered platform with intelligent workflow automation and actionable insights. | $10.5M / Venture - Series Unknown / Aug 20, 2024 | |
Prana Thoracic
|
Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Jun 18, 2024 | |
| See all 17 investments → | |||
Co-Investors
General Catalyst
4 deals together
1984 Ventures
2 deals together
Alexandria Venture Investments
2 deals together
AlleyCorp
2 deals together
Alumni Ventures
2 deals together
Fitz Gate Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does TMC Venture Fund invest in?
TMC Venture Fund invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did TMC Venture Fund last invest?
The most recent investment recorded for TMC Venture Fund closed in Mar 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
